Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push

The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform

New diabetes drug UBT251 shows strong phase 2 results in China

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats

Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff

Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem

Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY

rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells

Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids

The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories

PAI Pharma acquires Nivagen to boost US injectable drug production

The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing